News brief
On 2026-08-01, according to Xiniu Data, Anda Biotechnology completed Series A+ financing for an undisclosed amount. Investors were lead investor Anhui Hongtaihekang Phase One Venture Capital Fund Partnership (Limited Partnership), participating investor Beijing Changping Industry Development Investment Fund (Limited Partnership), participating investor Feixizipeng Venture Capital Partnership (Limited Partnership), participating investor Hefei Guoshengweilaikezhuan Venture Capital Fund Partnership (Limited Partnership). The company is a developer of personalized oncology neoantigen vaccines.
Connected profiles
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年8月01日，据烯牛数据报道，安达生物完成A+轮融资，金额未披露。投资方为安徽洪泰合康一期创业投资基金合伙企业（有限合伙）领投，北京昌平产业发展投资基金（有限合伙）、肥西紫蓬创业投资合伙企业（有限合伙）、合肥国生未来科转创业投资基金合伙企业（有限合伙）跟投。该公司为个性化肿瘤新抗原疫苗研发商。